Full Press Release Details
BOULDER, Colo.,Aug. 25, 2025/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its ENABLE Phase 1a/1bclinical trial of ELVN-001 in both an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting, taking placeSeptember 3-6, 2025, at the George R. Brown Convention Center inHouston, Texas. This is an encore presentation of data that were previously presented at the European Hematology Association (EHA) 2025 Congress.
Details of the presentation are as follows:Title:ENABLE: A Phase 1a/1bStudy of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid LeukemiaPresenter:Michael J. Mauro, M.D.Poster Session Date/Time:Wednesday, September 3,6:25 p.m. CDTPoster Location:Hall B3, Level 3Poster Number:CML-575Oral Session Title:Session V: Chronic Myeloid LeukemiaOral Session Date/Time:Thursday, September 4, 11:40 –11:50 a.m. CDT
Following the presentation, a copy will be available on the "Program Presentations & Publications" section of the Company's website athttps://www.enliventherapeutics.com.
About Enliven TherapeuticsEnliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based inBoulder, Colorado.
Forward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and potential of our small molecule therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: Enliven's limited operating history and resources; uncertainty in our ability to advance product candidates through clinical development, obtain regulatory approvals, and successfully commercialize or license them; uncertainty of preclinical and early clinical results, which may not predict success of later clinical trials; potential delays or challenges in clinical trial enrollment, data reliability, and patient retention; potential competition from other therapies; the decision to seek collaborations and develop combination therapies; the ability to hire and retain key personnel; our ability to obtain, maintain and enforce intellectual property for our product candidates; our reliance on third parties for manufacturing, research, and partnerships; geopolitical, market, and macroeconomic conditions; the ability to secure additional capital to support Enliven's operations and R&D; and other risks and uncertainties, including those more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), which may be found in the section titled "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and 10-Q filed with the SEC and in Enliven's future reports to be filed with the SEC. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.